박영준

All filings by 박영준 on record concern 티앤알바이오팹, in the capacity of chief executive. Over a trading history stretching from 6 February 2026 to 14 April 2026, the count stands at 2 filings.

No open-market sale appears; the market trades are 2 purchases worth €16k. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.

Most recently, on 20 April 2026, the filings show an open-market purchase worth €16k in 티앤알바이오팹. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.